WO2008112836A3 - Pharmaceutical composition comprising human growth hormon - Google Patents

Pharmaceutical composition comprising human growth hormon Download PDF

Info

Publication number
WO2008112836A3
WO2008112836A3 PCT/US2008/056757 US2008056757W WO2008112836A3 WO 2008112836 A3 WO2008112836 A3 WO 2008112836A3 US 2008056757 W US2008056757 W US 2008056757W WO 2008112836 A3 WO2008112836 A3 WO 2008112836A3
Authority
WO
WIPO (PCT)
Prior art keywords
human growth
pharmaceutical composition
growth hormone
suppository
active ingredient
Prior art date
Application number
PCT/US2008/056757
Other languages
French (fr)
Other versions
WO2008112836A2 (en
Inventor
Ashish Binpin Patel
Moise Azria
Shoufeng Li
Original Assignee
Novartis Ag
Ashish Binpin Patel
Moise Azria
Shoufeng Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Ashish Binpin Patel, Moise Azria, Shoufeng Li filed Critical Novartis Ag
Publication of WO2008112836A2 publication Critical patent/WO2008112836A2/en
Publication of WO2008112836A3 publication Critical patent/WO2008112836A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention pertains to a suppository that enables the successful delivery of human growth hormone (hGH), to a subject via administration of said suppository and provides pharmaceutical compositions which are suppositories comprising a human growth hormone as the active ingredient together with the delivery agent 5-CNAC, where the pharmaceutical provides bioavailability, e.g. satisfactory or optimal rectal bioavailability for the human growth hormone active ingredient.
PCT/US2008/056757 2007-03-15 2008-03-13 Pharmaceutical composition comprising human growth hormon WO2008112836A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89496107P 2007-03-15 2007-03-15
US60/894,961 2007-03-15

Publications (2)

Publication Number Publication Date
WO2008112836A2 WO2008112836A2 (en) 2008-09-18
WO2008112836A3 true WO2008112836A3 (en) 2008-12-04

Family

ID=39705333

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/056757 WO2008112836A2 (en) 2007-03-15 2008-03-13 Pharmaceutical composition comprising human growth hormon

Country Status (1)

Country Link
WO (1) WO2008112836A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030271B2 (en) 2005-07-05 2011-10-04 Emisphere Technologies, Inc. Compositions and methods for buccal delivery of human growth hormone
AU2010207725B2 (en) 2009-01-22 2015-06-11 Novo Nordisk Health Care Ag Stable growth hormone compounds
RU2012134974A (en) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг STABILIZED GROWTH HORMONE COMPOUND

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007009383A1 (en) * 2005-07-19 2007-01-25 Genescience Pharmaceuticals Co., Ltd. A rectum suppository of protein and its preparation method and the use
WO2008027854A2 (en) * 2006-08-31 2008-03-06 Novartis Ag Pharmaceutical compositions comprising hgh for oral delivery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007009383A1 (en) * 2005-07-19 2007-01-25 Genescience Pharmaceuticals Co., Ltd. A rectum suppository of protein and its preparation method and the use
WO2008027854A2 (en) * 2006-08-31 2008-03-06 Novartis Ag Pharmaceutical compositions comprising hgh for oral delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200725, Derwent World Patents Index; AN 2007-254433, XP002494163 *

Also Published As

Publication number Publication date
WO2008112836A2 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
WO2009086400A3 (en) Recombinant vwf formulations
WO2009007714A3 (en) Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour
MX2018005193A (en) Dual function proteins and pharmaceutical composition comprising same.
EA200802170A1 (en) LYOPHILIZED COMPOSITION OF THERAPEUTIC PEPTIDE ANTIBODY
IL194638A0 (en) Pharmaceutical compositions of hglp-1, exendin-4 and analogs thereof
IN2012DN02861A (en)
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
EP1885334A4 (en) A delivery system for two or more active components as part of an edible composition
PL2081547T3 (en) Galenic form for the trans-mucosal delivery of active ingredients
EP3972584A4 (en) Nanoemulsion compositions comprising biologically active ingredients
WO2006051110A3 (en) Stable formulations of insulinoptropic peptides
TW200745334A (en) Compositions and methods for producing a composition
WO2008051942A3 (en) Farnesoid x receptor agonists
MX2009004862A (en) Stabilization of vaccines by lyophilization.
WO2006017251A3 (en) Compositions for delivering peptide yy and pyy agonists
WO2005112633A3 (en) Compounds and compositions for delivering active agents
ZA201002812B (en) Parathyroid hormone formulations and uses thereof
EP3659585A4 (en) Composition for delivering physiologically active ingredients into blood vessel
PT2073789T (en) A stable composition comprising a bone anabolic protein, namely a pthrp analogue, and uses thereof
WO2008112368A3 (en) Phenylalkylcarboxylic acid delivery agents
WO2011062437A3 (en) Gonadotropin releasing hormone receptor antagonists, manufacturing method thereof, and pharmaceutical composition containing same
WO2009158412A8 (en) Sustained delivery of exenatide and other polypeptides
EA017091B9 (en) Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
MX336209B (en) Delivery of dry formulations of octreotide.
WO2007025988A3 (en) Liquid formulations of pegylated growth hormone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08743822

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08743822

Country of ref document: EP

Kind code of ref document: A2